We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Sanofi Consumer Healthcare India Limited ( ($IN:SANOFICONR) ) just unveiled an update. Sanofi Consumer Healthcare India ...

Sanofi Consumer Healthcare India Q4 Results 2025 on 21 Feb, 2025: Revenue decreased by 20.53% YoY & profit decreased by 34.66% YoY, profit at ₹44.3 crore and revenue at ₹170.7 crore.

As per provisional closing data, the barometer index, the S&P BSE Sensex, tumbled 424.90 points or 0.56% to 75,311.06. The Nifty 50 index declined 117.25 points or 0.51% to 22,795.90.

The Board of Directors of Sanofi Consumer Healthcare India Limited has recommended a final dividend of Rs. 55/- per equity share having face value of Rs.10/- each for the Financial Year ended 31st ...

The company faced headwinds in the December 2024 quarter (Q4) as it reported a significant decline in earnings.

Sanofi Consumer Healthcare India has reported 1% rise in net profit to Rs 46.35 crore on a 6.8% increase in net sales to Rs 170.70 crore in Q3 FY25 as compared with Q3 FY24.

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi is closer to selling a 50% controlling stake in the consumer health business, Opella to private equity Clayton ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi ( NASDAQ: SNY) has entered a share purchase agreement in relation to the sale of a 50% controlling stake in Opella, ...